Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97


CCR5 monoclonal antibodies for HIV-1 therapy.

Olson WC, Jacobson JM.

Curr Opin HIV AIDS. 2009 Mar;4(2):104-11. doi: 10.1097/COH.0b013e3283224015. Review.


Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1.

Murga JD, Franti M, Pevear DC, Maddon PJ, Olson WC.

Antimicrob Agents Chemother. 2006 Oct;50(10):3289-96.


Epitope switching as a novel escape mechanism of HIV to CCR5 monoclonal antibodies.

Jekle A, Chhabra M, Lochner A, Meier S, Chow E, Brandt M, Sankuratri S, Cammack N, Heilek G.

Antimicrob Agents Chemother. 2010 Feb;54(2):734-41. doi: 10.1128/AAC.00841-09. Epub 2009 Dec 7.


CCR5 small-molecule antagonists and monoclonal antibodies exert potent synergistic antiviral effects by cobinding to the receptor.

Ji C, Zhang J, Dioszegi M, Chiu S, Rao E, Derosier A, Cammack N, Brandt M, Sankuratri S.

Mol Pharmacol. 2007 Jul;72(1):18-28. Epub 2007 Mar 28.


Novel CCR5 monoclonal antibodies with potent and broad-spectrum anti-HIV activities.

Ji C, Brandt M, Dioszegi M, Jekle A, Schwoerer S, Challand S, Zhang J, Chen Y, Zautke L, Achhammer G, Baehner M, Kroetz S, Heilek-Snyder G, Schumacher R, Cammack N, Sankuratri S.

Antiviral Res. 2007 May;74(2):125-37. Epub 2006 Dec 5.


Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults.

Jacobson JM, Saag MS, Thompson MA, Fischl MA, Liporace R, Reichman RC, Redfield RR, Fichtenbaum CJ, Zingman BS, Patel MC, Murga JD, Pemrick SM, D'Ambrosio P, Michael M, Kroger H, Ly H, Rotshteyn Y, Buice R, Morris SA, Stavola JJ, Maddon PJ, Kremer AB, Olson WC.

J Infect Dis. 2008 Nov 1;198(9):1345-52. doi: 10.1086/592169.


Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection.

Li L, Tian JH, Yang K, Zhang P, Jia WQ.

Cochrane Database Syst Rev. 2014 Jul 26;(7):CD008439. doi: 10.1002/14651858.CD008439.pub3. Review.


Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults.

Jacobson JM, Lalezari JP, Thompson MA, Fichtenbaum CJ, Saag MS, Zingman BS, D'Ambrosio P, Stambler N, Rotshteyn Y, Marozsan AJ, Maddon PJ, Morris SA, Olson WC.

Antimicrob Agents Chemother. 2010 Oct;54(10):4137-42. doi: 10.1128/AAC.00086-10. Epub 2010 Jul 26.


Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140.

Trkola A, Ketas TJ, Nagashima KA, Zhao L, Cilliers T, Morris L, Moore JP, Maddon PJ, Olson WC.

J Virol. 2001 Jan;75(2):579-88.


Differential use of CCR5 by HIV-1 clinical isolates resistant to small-molecule CCR5 antagonists.

Henrich TJ, Lewine NR, Lee SH, Rao SS, Berro R, Gulick RM, Moore JP, Tsibris AM, Kuritzkes DR.

Antimicrob Agents Chemother. 2012 Apr;56(4):1931-5. doi: 10.1128/AAC.06061-11. Epub 2012 Jan 17.


The second extracellular loop of CCR5 contains the dominant epitopes for highly potent anti-human immunodeficiency virus monoclonal antibodies.

Zhang J, Rao E, Dioszegi M, Kondru R, DeRosier A, Chan E, Schwoerer S, Cammack N, Brandt M, Sankuratri S, Ji C.

Antimicrob Agents Chemother. 2007 Apr;51(4):1386-97. Epub 2007 Jan 22.


Monoclonal CCR5 antibody for treatment of people with HIV infection.

Li L, Sun T, Yang K, Zhang P, Jia WQ.

Cochrane Database Syst Rev. 2010 Dec 8;(12):CD008439. doi: 10.1002/14651858.CD008439.pub2. Review. Update in: Cochrane Database Syst Rev. 2014;7:CD008439.


Co-receptor antagonists as HIV-1 entry inhibitors.

Shaheen F, Collman RG.

Curr Opin Infect Dis. 2004 Feb;17(1):7-16. Review.


Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function.

Lee B, Sharron M, Blanpain C, Doranz BJ, Vakili J, Setoh P, Berg E, Liu G, Guy HR, Durell SR, Parmentier M, Chang CN, Price K, Tsang M, Doms RW.

J Biol Chem. 1999 Apr 2;274(14):9617-26.


CCR5 antibodies HGS004 and HGS101 preferentially inhibit drug-bound CCR5 infection and restore drug sensitivity of Maraviroc-resistant HIV-1 in primary cells.

Latinovic O, Reitz M, Le NM, Foulke JS, Fätkenheuer G, Lehmann C, Redfield RR, Heredia A.

Virology. 2011 Mar 1;411(1):32-40. doi: 10.1016/j.virol.2010.12.029. Epub 2011 Jan 12.


Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5.

Olson WC, Rabut GE, Nagashima KA, Tran DN, Anselma DJ, Monard SP, Segal JP, Thompson DA, Kajumo F, Guo Y, Moore JP, Maddon PJ, Dragic T.

J Virol. 1999 May;73(5):4145-55.


Synergistic Inhibition of R5 HIV-1 by the Fusion Protein (FLSC) IgG1 Fc and Maraviroc in Primary Cells: Implications for Prevention and Treatment.

Latinovic OS, Zhang J, Tagaya Y, DeVico AL, Fouts TR, Schneider K, Lakowicz JR, Heredia A, Redfield RR.

Curr HIV Res. 2016;14(1):24-36.


Identification of an unique CXCR4 epitope whose ligation inhibits infection by both CXCR4 and CCR5 tropic human immunodeficiency type-I viruses.

Adachi T, Tanaka R, Kodama A, Saito M, Takahashi Y, Ansari AA, Tanaka Y.

Retrovirology. 2011 Oct 22;8:84. doi: 10.1186/1742-4690-8-84.


Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection.

Lieberman-Blum SS, Fung HB, Bandres JC.

Clin Ther. 2008 Jul;30(7):1228-50. Review.


HIV-1 entry inhibitors: an overview.

Kuritzkes DR.

Curr Opin HIV AIDS. 2009 Mar;4(2):82-7. doi: 10.1097/COH.0b013e328322402e. Review.

Supplemental Content

Support Center